AAIC 2024: Eisai presents positive long-term data with Leqembi
Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.
02 August 2024
02 August 2024
Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.